Binosto

Active Ingredient(s): Alendronate Sodium
FDA Approved: * March 12, 2012
Pharm Company: * EFFRX PHARM. SA
Category: Osteoporosis

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Binosto Overview

Alendronic acid, also known as alendronate, is a bisphosphonate medication used to treat osteoporosis and Paget disease of bone.[1] It is taken by mouth.[1] Use is often recommended together with vitamin D, calcium supplementation, and lifestyle changes.[1] Common side effects include constipation, abdominal pain, nausea, and gastroesophageal reflux disease.[1] Serious side effects may include esophageal problems, osteonecrosis o...

Read more Binosto Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Alendronate

Recent Binosto Forums:

Possible Dosages for this and Related Drugs:

NDC Database Records for Binosto: (1 result)

Sorted by National Drug Code

• 0178-0101 Binosto 0.583 mg/ml Oral Solution by Mission Pharmacal Company

Other drugs which contain Alendronate Sodium or a similar ingredient: (4 results)

• ALENDRONATE 16 discussions
• FOSAMAX Alendronate21 discussions
• ALENDRONATE SODIUM + CHOLECALCIFEROL 1 discussion
• FOSAMAX PLUS D Alendronate Sodium + Cholecalciferol